全文获取类型
收费全文 | 1537317篇 |
免费 | 115487篇 |
国内免费 | 17838篇 |
专业分类
耳鼻咽喉 | 21510篇 |
儿科学 | 42260篇 |
妇产科学 | 41377篇 |
基础医学 | 211656篇 |
口腔科学 | 43193篇 |
临床医学 | 141727篇 |
内科学 | 291187篇 |
皮肤病学 | 32187篇 |
神经病学 | 117728篇 |
特种医学 | 61441篇 |
外国民族医学 | 573篇 |
外科学 | 227769篇 |
综合类 | 65462篇 |
现状与发展 | 61篇 |
一般理论 | 454篇 |
预防医学 | 104077篇 |
眼科学 | 37694篇 |
药学 | 121603篇 |
192篇 | |
中国医学 | 15210篇 |
肿瘤学 | 93281篇 |
出版年
2021年 | 18505篇 |
2020年 | 13385篇 |
2019年 | 15296篇 |
2018年 | 19461篇 |
2017年 | 16411篇 |
2016年 | 16962篇 |
2015年 | 21817篇 |
2014年 | 28823篇 |
2013年 | 35524篇 |
2012年 | 48414篇 |
2011年 | 52187篇 |
2010年 | 30893篇 |
2009年 | 28109篇 |
2008年 | 44204篇 |
2007年 | 47235篇 |
2006年 | 47999篇 |
2005年 | 46914篇 |
2004年 | 41709篇 |
2003年 | 40350篇 |
2002年 | 38803篇 |
2001年 | 67654篇 |
2000年 | 69864篇 |
1999年 | 60445篇 |
1998年 | 17944篇 |
1997年 | 16781篇 |
1996年 | 15648篇 |
1995年 | 14745篇 |
1994年 | 13543篇 |
1992年 | 44390篇 |
1991年 | 42656篇 |
1990年 | 41631篇 |
1989年 | 40437篇 |
1988年 | 37784篇 |
1987年 | 37062篇 |
1986年 | 35467篇 |
1985年 | 33533篇 |
1984年 | 25079篇 |
1983年 | 21233篇 |
1979年 | 24002篇 |
1978年 | 17049篇 |
1977年 | 14797篇 |
1976年 | 13346篇 |
1975年 | 15250篇 |
1974年 | 18081篇 |
1973年 | 17560篇 |
1972年 | 16823篇 |
1971年 | 15717篇 |
1970年 | 14891篇 |
1969年 | 14338篇 |
1968年 | 13451篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
131.
132.
133.
134.
刘洁荣 《中国医学教育技术》2015,(4)
世界各地均在加速推进教育信息化建设,但快速的 e 化发展,会因民众自身条件的不同造成不均的现象,并导致阶层、地域及群体间的“数位落差”。数位落差是世界各地政府在推动信息化的过程中都无法避免的,大陆地区也不例外。由于中国台湾地区具有与大陆相似的文化氛围和相近的教育发展历史,该文通过梳理和解读中国台湾地区现有的缩减数位落差政策,以期为大陆地区研制专门化政策来应对当前挑战,推进教育信息化的均衡发展提供借鉴。 相似文献
135.
136.
137.
David M. Presby Michael C. Rudolph Vanessa D. Sherk Matthew R. Jackman Rebecca M. Foright Kenneth L. Jones Julie A. Houck Ginger C. Johnson Janine A. Higgins P. Darrell Neufer Robert H. Eckel Paul S. MacLean 《Diabetes》2021,70(4):867
Moderate weight loss improves numerous risk factors for cardiometabolic disease; however, long-term weight loss maintenance (WLM) is often thwarted by metabolic adaptations that suppress energy expenditure and facilitate weight regain. Skeletal muscle has a prominent role in energy homeostasis; therefore, we investigated the effect of WLM and weight regain on skeletal muscle in rodents. In skeletal muscle of obesity-prone rats, WLM reduced fat oxidative capacity and downregulated genes involved in fat metabolism. Interestingly, even after weight was regained, genes involved in fat metabolism were also reduced. We then subjected mice with skeletal muscle lipoprotein lipase overexpression (mCK-hLPL), which augments fat metabolism, to WLM and weight regain and found that mCK-hLPL attenuates weight regain by potentiating energy expenditure. Irrespective of genotype, weight regain suppressed dietary fat oxidation and downregulated genes involved in fat metabolism in skeletal muscle. However, mCK-hLPL mice oxidized more fat throughout weight regain and had greater expression of genes involved in fat metabolism and lower expression of genes involved in carbohydrate metabolism during WLM and regain. In summary, these results suggest that skeletal muscle fat oxidation is reduced during WLM and regain, and therapies that improve skeletal muscle fat metabolism may attenuate rapid weight regain. 相似文献
138.
随着腔镜技术的进一步发展以及微创理念应用于结直肠外科疾病的诊治中,结直肠相关疾病的诊治发生了翻天覆地的变化。由传统的经腹手术到腹腔镜手术、经自然腔道手术,再到经自然腔道取标本手术(NOSES),结直肠疾病的外科诊治在微创领域取得了巨大成果。NOSES技术是目前结直肠外科在微创领域前沿的手术方式之一,它通过经直肠、阴道取标本来避免了腹壁的辅助取标本切口,从而将结直肠外科手术进一步微创化。NOSES技术集传统腹腔镜手术的优势与现代微创外科的理念于一体,它在确保手术效果的基础上集中体现了微创、加速康复外科、功能外科、"无疤"等理念的特点。本文主要就国内外各中心开展NOSES技术在结直肠外科诊治开展中的相关经验、心得和体会进行综述。 相似文献
139.
J. Savige L. Amos Frank Ierino H. G. Mack R. C. Andrew Symons P. Hughes 《Ophthalmic genetics》2016,37(4):369-376
Background: Dense deposit disease and atypical hemolytic uremic syndrome are often caused by Complement Factor H (CFH) mutations. This study describes the retinal abnormalities in dense deposit disease and, for the first time, atypical haemolytic uremic syndrome. It also reviews our understanding of drusen pathogenesis and their relevance for glomerular disease. Methods: Six individuals with dense deposit disease and one with atypical haemolytic uremic syndrome were studied from 2 to 40 years after presentation. Five had renal transplants. All four who had genetic testing had CFH mutations. Individuals underwent ophthalmological review and retinal photography, and in some cases, optical coherence tomography, and further tests of retinal function. Results: All subjects with dense deposit disease had impaired night vision and retinal drusen or whitish-yellow deposits. Retinal atrophy, pigmentation, and hemorrhage were common. In late disease, peripheral vision was restricted, central vision was distorted, and there were scotoma from sub-retinal choroidal neovascular membranes and atypical serous retinopathy. Drusen were present but less prominent in the young person with atypical uremic syndrome due to a heterozygous CFH mutation. Conclusions: Drusen are common in forms of C3 glomerulopathy caused by compound heterozygous or heterozygous CFH mutations. They are useful diagnostically but also impair vision. Drusen have an identical composition to glomerular deposits. They are also identical to the drusen of age-related macular degeneration, and may respond to the same treatments. Individuals with a C3 glomerulopathy should be assessed ophthalmologically at diagnosis, and monitored regularly for vision-threatening complications. 相似文献
140.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献